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linical position of mitochondrial diseases
Mitochondrial diseases appear as various systemic organ disor-
ers mainly observed in brain, nerve, skeletal muscle, and heart
hich are organs with higher necessity of energy [1,2]. Mito-
hondrial malfunction usually results in reduction in adenosine
riphosphate production and leads these organs to a shortness of
etabolic energy as well as hyper-production of pyruvate or lac-
ic acid [1]. Representative appearance of clinical mitochondrial
ncephalomyopathy can be classiﬁed as chronic progressive exter-
al ophthalmoplegia, myoclonic epilepsy with ragged red ﬁbers
nd mitochondrial myopathy, encephalopathy, lactic acidosis, and
troke-like episodes (MELAS) [1]. Mitochondrial cardiomyopathy is
Fig. 1. Problems in clinical trials of therapies for orphan disease [2].ig. 2. Concepts of possible therapeutic materials for mitochondrial diseases [2]. CPT, carnitine palmitoyltransferase; DCA, dichloroacetic acid; PC, phosphatidyl choline;
DHC, pyruvate dehydrogenase complex; TCA, tricarboxyl acid; ANT1, adenine nucleotide translocator 1; ATP, adenosine triphosphate; ADP, adenosine diphosphate; CK,
reatine  kinase; NADH2, dihydro-nicotineamide adenine dinucleotide; FADH2, dihydro-ﬂavin adenine dinucleotide. * speciﬁc transporter.
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lso a phenotype of mitochondrial disease and is deﬁned as abnor-
al structure and/or function of cardiac tissue caused by genetic
bnormality involving mitochondrial respiratory chain without any
ther known heart disease [3–5]. These and the other types of
itochondrial diseases are rarely observed and termed as “orphan
isease” and the population of the patients is considered less than
0,000 in total in Japan. Because of such a situation, even a precise
lassiﬁcation as well as clinical trials for therapeutic approaches is
imited (Fig. 1) [2]. Probably, the replenishment of lacking enzyme
n abnormal mitochondria will be a fundamental approach, but
uch methodology cannot be anticipated because of restricted
ransferring function of mitochondria membrane.
ossible pharmacological therapy for mitochondrial
iseases
Concepts of possible therapeutic materials for mitochondrial
iseases are summarized in Fig. 2 [1,2]. None of these materials
ere proven to be effective for any type of mitochondrial disease
nd all of the trials for the treatment involve off-label use. The
ost recent review, i.e. Cochrane Review 2006 [6], has realized
he absence of any effective therapy for mitochondrial diseases,
ut it also mentioned several interesting reports. They were the
eports about coenzyme Q10, creatine, dichloroacetic acid (DCA),
nd dimethylglycine as the therapeutic materials but the results
ere controversial [7,8]. However, some clinical trials, such as
oenzyme Q10 for mitochondrial diseases, DCA for MELAS, and
debenone for Leber hereditary optic neuropathy are still on going.
he possibilities of resveratorol and l-arginine have also been sug-
ested by several reports [9,10]. In the case report of Vahdat et al.
11], a catastrophic condition of diseased heart was dramatically
mproved by the administration of a unique “mitochondrial cock-
ail” which contained respiratory chain co-factors (coenzyme Q10,
hiamine, riboﬂavin), antioxidant (vitamin-E), biochemical mate-
ials (l-carnitine, creatine, folate), and vasodilator (l-arginine).
lthough the diagnosis itself of the patient was controversial, the
ffect of this therapeutic approach was dramatic and cardiac con-
ition almost fully recovered at least in this case. Although it will
e difﬁcult to clarify the role of each material in this unique cock-
ail in mitochondrial diseases, this kind of “broad approach” might
e effective in various types of mitochondrial diseases [12–14] and
ay  show a novel pharmacological approach to mitochondrial dis-
ases. However, strong attention should be paid to the dosage and
ethod of administration of these materials because they can cause
arious types of side effects, including hypotension, peripheral vas-
ular injury, cardiogenic shock, or life-threatening arrhythmias. The Cases 6 (2012) e64–e65 e65
protocol for such broad therapy should be constructed carefully by
considering case-by-case situations.
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